Kornimate/medical-research-clean huggingface dataset:
natural history of clostridioides difficile infection

Conditions: Clostridium Difficile Infection; Health Care Associated Infection; Nosocomial Infection

Summary: aim: to investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of clostridioides difficile infection (cdi). to generate a predictive tool based on epidemiological, clinical, genetic and microbiologic variables aimed to identify patients at a higher risk of cdi recurrence in a context of optimized icd management. design: multicenter prospective cohort study. patients: older than 18 years patients with cdi diagnosis, made by idsa criteria, in the participant centers. follow-up: a stewarship program aimed to improve cdi management, including early detection of cdi recurrence, will be implemented in the participant centers. blood samples for genetic testing and stool samples for intestinal microbiome studies will be collected. variables and data analysis: the primary outcome variable will be the emergence of cdi recurrence. potential independent predictors of recurrence, including genetic and microbiological factors, will be assessed. a predictive tool based on independent predictors of recurrence will be built in a development subpopulation. the performance of the model will be assessed by roc curves, and sensititvity, especificity, as well as negative and positive predictive values will be calculated, both in the development subpopulation and in a validation subset.


Eligibility criteria:
inclusion criteria: * age older than 18 years * new episode of clostridioides difficile infection, based on idsa criteria. exclusion criteria: - none

Keywords: clostridioides difficile clostridium difficile nosocomial diarrhea health care associated infection nosocomial infection antimicrobial stewardship
clinical pilates' impact on fitness, symptoms & kinesiophobia in pms

Conditions: Premenstrual Syndrome; Pilates Exercise

Summary: premenstrual syndrome (pms) is characterized by a series of somatic and psychological symptoms of varying severity that occur during the luteal phase of the menstrual cycle, affecting approximately 30% of women and resolving with menstruation. these symptoms impact daily activities, interpersonal relationships, social engagements, work efficiency, and educational productivity. pms manifests with physical symptoms such as breast swelling and tenderness, fatigue, headaches, and weight gain, as well as psychological and emotional symptoms such as mood disorders, irritability, and stress. symptoms typically subside with the onset of menstruation. there is no single accepted treatment for pms. due to conflicting findings in studies, various treatment methods are used, including lifestyle modifications, education, stress management techniques (such as massage, reflexology, and yoga), exercise, or medical support. regular exercise is known to improve overall well-being. it prevents the decrease in endorphin secretion during the luteal phase of the menstrual cycle and has a positive impact on pms symptoms, particularly mood disorders, fluid retention, and breast tenderness. pilates-based exercise training is an approach that enhances muscle stability through effective, controlled movements while strengthening muscle groups associated with pain. clinical pilates-based exercise training is considered a preferable method for pms management, as it is believed to improve functional capacity, pain management, mood disorders, endurance, flexibility, symptom severity, and fear of movement in individuals with pms. due to the limited number of studies in the literature on pms, our study aims to investigate the effects of a clinical pilates-based exercise program on functional fitness parameters, symptom severity, and kinesiophobia.


Eligibility criteria:
inclusion criteria: * having premenstrual syndrome (pms) * being able to read and understand turkish * willingness to participate in the study exclusion criteria: * being in menopause or perimenopause * being pregnant * currently participating in or having engaged in a regular exercise program (other than clinical pilates) within the past year * having comorbid orthopedic, musculoskeletal, psychological, or cardiovascular conditions that may affect test evaluations

Keywords: premenstrual syndrome physical fitness kinesiophobia clinic pilates
influence of antiretroviral regimen on immune reconstitution in the female genital tract

Conditions: Women's Health; HIV Infection; Genital Diseases, Female

Summary: increases in cluster of differentiation 4 (cd4)+ t cells in the blood is well documented in human immunodeficiency virus (hiv)-infected individuals after starting antiretroviral therapy (art), but increases cd4+ t cells in the cervix is variable and not fully understood. although the amount of hiv in the vagina declines in parallel with those in the plasma when antiretroviral therapy for hiv is started, hiv is still detected frequently in cervical samples from women with undetectable plasma viral loads, suggesting that low level viral replication in the female vaginal tract could lead to both inflammation and incomplete increases in cd4+ t cells. two classes of hiv medications, nonnucleoside analogue reverse transcriptase inhibitors and protease inhibitors are substantially lower in the female genital tract compared to plasma, whereas concentrations of another class, nucleos(t)ide analogue reverse transcriptase inhibitors are similar or higher to those found in plasma. thus, many widely used first-line three drug hiv therapies only achieve high concentrations of only two medications in the female genital tract. importantly, with the recent development of raltegravir (ral), which achieves concentrations in the female genital tract higher than those in plasma, art regimens that deliver high concentrations of 3 antiretroviral drugs to the female genital tract are now available. the investigators hypothesize that cervical cd4+ t cell reconstitution is better and inflammatory markers are lower in hiv-infected women on a hiv-therapy including tenofovir (tdf) and emtricitabine (ftc) with ral versus ritonavir (rit)-boosted atazanavir (atz), and that this is due to therapeutic concentrations of 3 versus 2 antiretroviral drugs in the female genital tract.


Eligibility criteria:
inclusion criteria: * hiv-1 seropositive women receiving a ral-based regimen (n=20) and women receiving an atazanavir-based regimen (n=20). * women will be recruited to this study from the denver metropolitan area. * the women must have a plasma hiv rna \ 300 cell/mm3. * transient increases of \<=200 copies hiv-1 rna copies/ ml will be allowed. exclusion criteria: * hysterectomy * no a menstrual cycle for 12 months * active substance abuse * hematocrit (hct) \<30 * bleeding diathesis * known carcinoma of the cervix * using oral glucocorticoids or other immunosuppressive agents * current pregnancy

Keywords: immune reconstitution cd4+ t cells
the effect of mirror therapy applied to stroke patients on motor-sensory status and quality of life

Conditions: Stroke; Mirror Movement Therapy; Rehabilitation

Summary: purpose: the research will be conducted to evaluate the effect of mirror therapy applied to stroke patients on motor-sensory status and quality of life. method: the research will be carried out as a randomized controlled experimental study at bilecik training and research hospital and bozüyük state hospital between 01.08.2024-01.05.2025. the population of the research consists of 350 people. individuals will be distributed to the experimental (30) and control (30) groups by simple randomization method. in collecting research data; the patient introduction form, brunnstrom staging and sf-36 quality of life scale will be administered to the patients in both groups by the researcher using face-to-face interview technique (pre-test). patients in the experimental group will be informed about mirror therapy. in addition to conventional rehabilitation, patients in the experimental group will receive mirror therapy for 30 minutes, 4 times a week for 4 weeks. patients in the control group will only receive conventional rehabilitation for 30 minutes, 4 times a week for 4 weeks. at the end of the 4th week, patients in both groups will be administered brunnstrom staging and sf-36 quality of life scale (posttest). if both groups are discharged before 4 weeks, the planned practices will continue at home.


Eligibility criteria:
inclusion criteria: 1. being literate, 2. being over the age of 18, 3. having sufficient communication skills to answer oral and written questions and follow instructions, 4. having been diagnosed with a stroke and at least 6 days have passed since it occurred, 5. not having severe vision problems, 6. not having a vertigo problem, 7. not having been diagnosed with epilepsy, 8. upper extremity stage 2 and above in brunnstrom staging 9. lower extremity stage 2 and above in brunnstrom staging exclusion criteria: 1. being under 18 years of age 2. upper extremity stage 2 and below in brunnstrom staging 3. in brunnstrom staging, lower extremity stage 2 and below

Keywords: stroke mirror movement therapy rehabilitation
clinical impacts of achieving svr in patients with advanced hepatic fibrosis related to chronic hcv treated with direct acting antivirals

Conditions: HCC in Chronic HCV Patients With Advanced Liver Fibrosis

Summary: chronic hcv infection has relatively slow rate of progression. liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) \[6\]. once cirrhosis is established the disease progression remains unpredictable: cirrhosis can remain indolent for many years in some patients whilst progressing in others to hcc, hepatic decompensation and death. overall once cirrhosis has developed there is a 1-5% annual risk of hcc and a 3-6% annual risk of hepatic decompensation. following an episode of decompensation the risk of death in the following year is between 15% and 20% treatment of chronic hcv has been dramatically changed in the last few years with introduction of direct acting antivirals (daas). the new therapies with excellent safety profiles, shorter duration of therapy and marked higher efficacy can be even used in patients with advanced fibrosis and cirrhosis

chronic hcv infection has relatively slow rate of progression. liver fibrosis is the main sequlae and usually progressed to cirrhosis after long period (10 to 20 years) \[6\]. once cirrhosis is established the disease progression remains unpredictable: cirrhosis can remain indolent for many years in some patients whilst progressing in others to hcc, hepatic decompensation and death. overall once cirrhosis has developed there is a 1-5% annual risk of hcc and a 3-6% annual risk of hepatic decompensation. following an episode of decompensation the risk of death in the following year is between 15% and 20% treatment of chronic hcv has been dramatically changed in the last few years with introduction of direct acting antivirals (daas). the new therapies with excellent safety profiles, shorter duration of therapy and marked higher efficacy can be even used in patients with advanced fibrosis and cirrhosis

Eligibility criteria:
inclusion criteria: * above 12 years old * fibroscan f3 or f4 * hcv positive * received daas exclusion criteria: * below 12 years old * fibroscan below f3 * hcv negative

Keywords: hcc, chronic hepatitis c, hepatitis c, liver fibrosis
observational study of osseotite certain tapered implants in immediate loading cases

Conditions: Partial Edentulism; Tooth Disease

Summary: osseotite certain tapered implants placed in immediate prosthesis loaded cases.

osseotite certain tapered implants are placed and restored immediately (during the same visit)

Eligibility criteria:
inclusion criteria: * patients of either sex and older than 18 years of age * patients needing at least one dental implant to treat partial edentulism * patients physically able to tolerate surgical and restorative dental procedures * patients agreeing to all protocol visits exclusion criteria: * patients with infection or severe inflammation at the intended treatment sites * patients smoking greater than 10 cigarettes per day * patients with uncontrolled diabetes mellitus * patients with uncontrolled metabolic diseases * patients who received radiation treatment to the head in the past 12 months * patients needing bone grafting at the intended treatment sites * patients known to be pregnant at screening visit * patients with para-functional habits like bruxing and clenching

Keywords: edentulism dental implants osseotite certain tapered randomized clinical study partial edentulism immediate loading crestal bone level
a clinical trial to investigate the pharmacokinetic drug interaction between yhr1705 and yhr1706

Conditions: Dyslipidemia; Type 2 Diabetes Mellitus

Summary: this is a phase 1, open label, multiple-dose, crossover clinical trial to investigate the pharmacokinetic drug interaction between yhr1705 and yhr1706 in healty male volunteers

this is an open-label, randomized, 6-sequence, 3-period crossover study. subjects will receive multiple oral doses of yhr1705, yhr1706 or yhr1705 + yhr1706 qd for 5 consecutive days. there will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period.

Eligibility criteria:
inclusion criteria: * healthy male with body mass index(bmi) between 18.5 and 30 kg/m2 * who has not suffered from clinically significant disease * provision of signed written informed consent exclusion criteria: * history of and clinically significant disease * a history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs * administration of other investigational products within 3 months prior to the first dosing * volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ecgs, or vital signs
an observational study of mabthera/rituxan (rituximab) in patients with relapsing or refractory chronic lymphocytic leukemia

Conditions: Lymphocytic Leukemia, Chronic

Summary: this multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (cll) patients. data will be collected for 2 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * diagnosis of relapsed or refractory chronic lymphocytic leukemia (cll) with first or second relapse * previous treatment with mabthera/rituxan * mabthera/rituxan treatment planned for current relapse exclusion criteria: * richter syndrome * life expectancy \<6 months
effects of agility and perturbation based training in addition to routine physical therapy

Conditions: Knee Osteoarthritis

Summary: osteoarthritis is a degenerative joint disease. knee oa patients sometimes report episodes of knee instability that limit their adls. the episodes of instability are similar to those reported in knee ligament injuries. it is believed that modifications of interventions that are used to promote knee stability in knee ligament injuries can be used in knee oa to enhance knee stability and function. the purpose of this study will be to determine the effects of agility and perturbation-based training in addition to routine physical therapy on pain, function, quality of life and disability in knee osteoarthritis.

a randomized clinical trial will be conducted at al syed touqeer altaf surgical hospital through a convenience sampling technique on 26 patients, which will be allocated using computer-generated randomization into two groups. group a will be treated with agility and perturbation training techniques in addition to the same routine physical therapy as group b, and group b will receive only routine physical therapy. outcome measures will be conducted through nprs, womac, sf-36, and kos-adls questionnaires. all the outcome measures will be assessed pre and post-treatment, and the assessor will be blind. frequency of the treatment will be 3 sessions per week for 4 weeks. data will be analyzed using spss software version 25.

Eligibility criteria:
inclusion criteria: * both male and female. * subjects with kellgren and lawrence grade ii and iii osteoarthritis. * oa diagnosed subjects according to american college of rheumatology acr criteria; * morning stiffness ≤ 30 minutes. * crepitus with active motion of the knee (while weight bearing). * tenderness to palpation of the bony margins of the joint, bony enlargement, and no palpable warmth. exclusion criteria: * ligament or meniscal injury around the knee. * suffering from acute synovitis * neuromuscular disorders. * cognitive impairments. * required use of an assistive device for ambulation. * reported a history of 2 or more falls within the previous year. * undergone total knee arthroplasty. * uncontrolled hypertension, history of cardiovascular disease, neurological disorders that affected lower extremity function. * severe visual problems.

Keywords: pain function quality of life
improvement in gross motor function and muscle tone in children with cerebral palsy related to neonatal icterus

Conditions: Cerebral Palsy

Summary: the purpose of this study is to evaluate the safety and effectiveness of stem cells for cerebral palsy related to neonatal icterus

the purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in 25 patients with cerebral palsy related to neonatal icterus at vinmec international hospital, hanoi, vietnam

Eligibility criteria:
inclusion criteria: * cerebral palsy of any types caused by neonatal icterus exclusion criteria: * epilepsy * hydrocephalus with ventricular drain * coagulation disorders * allergy to anesthetic agents * severe health conditions such as cancer, failure of heart, lung, liver or kidney * active infections

Keywords: cerebral palsy stem cells neonatal icterus
a study of faldaprevir, ribavirin and td-6450 in participants with genotype 4 hepatitis c virus infection

Conditions: Hepatitis C Viral Infection; Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 4

Summary: phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of faldaprevir and td-6450 in combination with ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis c virus (hcv) infection.

a study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with ribavirin in treatment-naïve participants with genotype 4 hepatitis c infection. the study will test the safety and effects of this alternative treatment for up to 12 weeks. secondary objectives of this study are to determine the pharmacokinetics of the study drugs when co-administered, and to evaluate hcv rna kinetics during treatment.

Eligibility criteria:
inclusion criteria: * chronic genotype 4 hepatitis c infection and hcv rna ≥ 10\^4 iu/ml at screening * hepatitis c virus treatment naive, defined as defined as having never received a direct acting anti-viral (daa), and as having received ≤ 8 weeks of interferon ≥ 6 months prior to screening * absence of cirrhosis as defined by one of the following: * a liver biopsy performed within 24 calendar months of day 1 showing absence of cirrhosis * transient elastography (fibroscan®) performed within 12 calendar months of day 1 with a result of ≤ 12.5 kpa * a fibrosure® score ≤ 0.48 and ast:platelet ratio (apri) ≤ 1 performed during screening exclusion criteria: * infection with hepatitis b virus (hbv) or human immunodeficiency virus, hiv-1 or hiv-2
laparoscopic adjustable gastric banding with truncal vagotomy

Conditions: Morbid Obesity; Obstructive Sleep Apnea; Hypertension; Urinary Incontinence; Hypertriglyceridemia; Diabetes; Hypercholesterolemia

Summary: laparoscopic adjustable gastric banding (lagb) is a gold standard in the surgical treatment of morbid obesity. we hypothesize that the addition of truncal vagotomy (cutting of nerves to the stomach) will produce greater weight loss and better reduction of co-morbidities (diseases caused by or aggravated by morbid obesity) than lagb alone. 25 patients will be enrolled and outcomes compared to lagb historical controls over a post-operative period of 24 months.

the patients will receive standard laparoscopic adjustable gastric banding treatment as well as truncal vagotomy. the vagus nerves will be cut just below the diaphragm using the same access ports that are used during the laparoscopic adjustable gastric banding. during the surgical procedure, the first fifteen patients will also receive a dose of baclofen, a vagus nerve stimulant, and an endoscopy at the end of the procedure during which congo red dye will sprayed within the stomach. the baclofen and endoscopy are used to ensure that all branches of the vagus nerve have been cut. if, after 15 complete vagotomies, are verified by the above testing then the use of baclofen and endoscopy will be abandoned.

Eligibility criteria:
inclusion criteria: 1. male or female patient between 18 to 60 years of age. 2. patient has body mass index (bmi) between 40 to 50 or a bmi between 35 to 40 with one or more co-morbidities , and a stable weight for the last 3 months (+ 3 kg). 3. female patients must be willing to use contraceptive methods during the course of the trial (18 months). 4. patient must be motivated to lose weight. 5. patient has a history of at least one professionally supervised 6 month attempt to lose weight or more than two serious attempts. 6. patient must be fully ambulatory. 7. patient is to sign and be given a copy of the written informed consent form. - exclusion criteria: 1. history or signs of prior gastric or esophageal surgery 2. history of or signs and/or symptoms of gastro-duodenal ulcer disease. 3. participation or plans for participation in another investigational study during the study period. 4. patients with large hiatal hernias. -

Keywords: laparoscopic adjustable gastric banding truncal vagotomy lap band lap banding obesity surgery bariatric surgery weight loss surgery
effect of moringa oleifera leaf on hemoglobin levels in anemia

Conditions: Anemia of Pregnancy

Summary: the main objective of this study was to compare the results of hemoglobin levels between pregnant women in the treatment group and the control group. participants will be subjected to anthropometric measurements, recall of food intake for 1 x 24 hours, check hemoglobin before and after being given the intervention and participants in the treatment group are given moringa leaf capsules and iron tablets while participants in the control group are only given iron tablets. researchers will compare the final results of hemoglobin levels between the treatment group and the control group


Eligibility criteria:
inclusion criteria: * pregnant women with 2nd and 3rd trimester of pregnancy * pregnant women with mild to moderate anemia at day 90 after treatment exclusion criteria : * hypotensive pregnant women * pregnant women with gemelli * pregnant women with chronic diseases (hepatitis and hiv)
a trial to compare american heart association (aha) and simple (sim)method to give adenosine to treat supra-ventricular tachycardia (svt)

Conditions: Supra-ventricular Tachycardia

Summary: study to compare non inferiority of giving adenosine with the simplified method vs the aha method

tle: a randomised controlled trial of the standard versus a simplified adenosine administration method in the treatment of adult patients with supra- ventricular tachycardia (svt

Eligibility criteria:
inclusion criteria: * svt * normal blood pressure * normal mentation * give consent exclusion criteria: * recent coffee * allergy to adenosine * asthma * cardiac operations